Gilead (GILD) and Kymera Therapeutics (KYMR) announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader program targeting cyclin-dependent kinase 2 with broad oncology treatment potential including in breast cancer and other solid tumors. Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures, the company noted. This transaction with Kymera is expected to reduce Gilead’s GAAP and non-GAAP 2025 EPS by approximately 2c-3c, the company stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead, Kymera enter license agreement for molecular glue degrader program
- Expected breakthrough year against H.I.V. fades as U.S. pulls support, NYT says
- Citi views Yeztugo as ‘key growth driver’ for Gilead
- Oppenheimer sees limited near-term impact from Gilead HIV approval
- BMO says lenacapavir approval for prevention a ‘major win’ for Gilead